Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
Sponsor: University of Illinois at Chicago
Summary
In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.
Official title: Phase II Study of the Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2025-08-01
Completion Date
2026-06-15
Last Updated
2026-01-29
Healthy Volunteers
No
Interventions
Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome
Eye Drops
Vehicle Control
Eye Drops
Locations (1)
University of Illinois at Chicago
Chicago, Illinois, United States